Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
IN8bio Inc (INAB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.83-10.82%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for INAB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce net operating losses toward -$5.1 million by 2026-Q1 | A primary condition in IN8bio Inc's published investment case. The stated target is net income losses <= -$5.1 million. | Improving | net income losses exceed -$5.1 million beyond 2026-Q1 | Net income: $-4.781M FY2026-Q2; GAAP. Published target: net income losses <= -$5.1 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-4,781,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth story, not a proven compounder, with high risk and weak recent financial performance. The long-term thesis is on watch: some programs are progressing, but the evidence snapshot gives low confidence.
The snapshot provides no valuation multiple or direct measure of market expectations, so whether INAB is cheap or expensive versus peers cannot be assessed. Recent performance is below its industry cohort, and the stock has reacted down, but the evidence does not show exactly what expectations are already reflected.
Near term, the company remains loss-making, and the next financial update carries elevated miss risk. The INB-600 and INB-619 platform is on track for preclinical animal data in the second half of 2026; glioblastoma data show progress, though the program and regulatory work remain under watch.
The multi-year thesis hinges on clinical progress, especially whether the glioblastoma program's results support further development and whether management secures useful FDA guidance. Near term, a guidance cut or weaker jobs data could weigh on the business backdrop, while continued strength from healthcare bellwethers could support sector sentiment.
Over the next one to three years, INAB's case rests on turning early program progress into credible clinical and regulatory milestones while managing the risks of a loss-making business. The evidence is mixed and confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “• Net loss: The Company reported a net loss of $4.8 million, or $0.25 per basic and diluted common share, for the three months ended June 30, 2026, compared with a net loss of $5.1 million, or $1.24 per basic and diluted common share, for the comparable prior year period.” “Second Quarter 2026 Financial Highlights • Cash position: As of June 30, 2026, the Company had cash of $18.0 million, compared with $13.2 million, for the comparable prior year period.”
Delivery assessment Nov 4, 2026Advance clinical trials of gamma-delta T cell therapies | The company is focused on cancer therapies with new cell treatments. | Intact | clinical trial progress stalls or fails | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Lower negative cash from operations to <= -$4.9 million by 2026-Q1 | Cash burn also improved from $6.1M to $4.9M. | Broken | cash burn exceeds -$4.9 million beyond 2026-Q1 | Cash from operations: $-3.745M FY2026-Q2; GAAP. Published target: cash from operations <= -$4.9 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-3,745,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “• Net loss: The Company reported a net loss of $4.8 million, or $0.25 per basic and diluted common share, for the three months ended June 30, 2026, compared with a net loss of $5.1 million, or $1.24 per basic and diluted common share, for the comparable prior year period.” “Second Quarter 2026 Financial Highlights • Cash position: As of June 30, 2026, the Company had cash of $18.0 million, compared with $13.2 million, for the comparable prior year period.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.06 → $-0.95 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.06 | $1,100,000 | 3 / 3 |
| 2026-07-25 | $-1.06 | $829,750 | 4 / 4 |
| 2026-07-26 | $-1.06 | $829,750 | 4 / 4 |
| 2026-07-27 | $-1.06 | $829,750 | 4 / 4 |
| 2026-07-28 | $-1.06 | $829,750 | 4 / 4 |
| 2026-07-29 | $-1.06 | $829,750 | 4 / 4 |
| 2026-07-30 | $-1.06 | $829,750 | 4 / 4 |
| 2026-07-31 | $-1.06 | $829,750 | 4 / 4 |
| 2026-08-01 | $-1.06 | $1,100,000 | 3 / 3 |
| 2026-08-02 | $-1.06 | $829,750 | 4 / 4 |
| 2026-08-03 | $-1.06 | $829,750 | 4 / 4 |
| 2026-08-04 | $-1.06 | $829,750 | 4 / 4 |
| 2026-08-05 | $-1.06 | $829,750 | 4 / 4 |
| 2026-08-06 | $-1.06 | $829,750 | 4 / 4 |
| 2026-08-07 | $-1.06 | $1,100,000 | 3 / 3 |
| 2026-08-08 | $-1.06 | $1,100,000 | 3 / 3 |
| 2026-08-09 | $-1.06 | $829,750 | 4 / 4 |
| 2026-08-10 | $-1.06 | $1,100,000 | 3 / 3 |
| 2026-08-12 | $-1.06 | $1,100,000 | 3 / 3 |
| 2026-08-13 | $-1.06 | $1,100,000 | 3 / 3 |
| 2026-08-14 | $-1.06 | $1,100,000 | 3 / 3 |
| 2026-08-15 | $-1.06 | $1,100,000 | 3 / 2 |
| 2026-08-16 | $-1.06 | $1,100,000 | 3 / 2 |
| 2026-08-17 | $-1.06 | $1,100,000 | 3 / 2 |
| 2026-08-18 | $-1.06 | $1,100,000 | 3 / 3 |
| 2026-08-19 | $-1.06 | $1,100,000 | 3 / 3 |
| 2026-08-20 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-21 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-22 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-23 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-24 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-25 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-26 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-27 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-28 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-29 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-30 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-08-31 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-01 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-02 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-03 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-04 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-05 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-06 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-07 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-08 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-09 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-10 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-11 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-12 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-13 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-14 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-15 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-16 | $-0.96 | $1,106,333 | 3 / 3 |
| 2026-09-17 | $-0.95 | $1,659,500 | 3 / 3 |
| 2026-09-18 | $-0.95 | $1,659,500 | 3 / 3 |
| 2026-09-19 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-20 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-21 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-22 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-23 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-24 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-25 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-26 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-27 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-28 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-29 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-09-30 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-01 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-02 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-03 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-04 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-05 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-06 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-07 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-08 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-09 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-10 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-11 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-12 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-13 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-14 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-15 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-16 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-17 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-18 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-19 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-20 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-21 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-22 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-23 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-24 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-25 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-26 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-27 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-28 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-29 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-30 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-10-31 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-11-01 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-11-02 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-11-03 | $-0.95 | $1,659,500 | 2 / 2 |
| 2026-11-04 | $-0.95 | $1,659,500 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.